Empagliflozin and the risk of heart failure hospitalization in routine clinical care: a first analysis from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study

BACKGROUND: The EMPA-REG OUTCOME trial showed that empagliflozin, a sodium-glucose co-transporter-2 inhibitor (SGLT2i), reduces the risk of hospitalization for heart failure (HHF) by 35%, on top of standard of care in patients with type 2 diabetes (T2D) and established CV disease (CVD). The EMPaglif...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Circulation
Main Authors: Patorno E, Elisabetta, Pawar, Ajinkya, Franklin, Jessica M, Najafzadeh, Mehdi, Déruaz-Luyet, Anouk, Brodovicz, Kimberly G., Sambevski, Steven, Bessette, Lily G., Santiago Ortiz, Adrian J., Kulldorff, Martin, Schneeweiss, Sebastian
Formato: Artigo
Idioma:Inglês
Publicado: 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6594384/
https://ncbi.nlm.nih.gov/pubmed/30955357
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.118.039177
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares